|
18 May 2021 |
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
|
|
18 May 2021 |
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
|
|
17 May 2021 |
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
|
|
17 May 2021 |
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
|
|
12 May 2021 |
INOVIO’s Pan-COVID-19 vaccine candidate (INO-4802) induces broad immunity against major viral variants in preclinical studies
|
|
12 May 2021 |
Providence Therapeutics Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19
|
|
11 May 2021 |
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
|
|
10 May 2021 |
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
|
|
08 May 2021 |
Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults
|
|
07 May 2021 |
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine
|
|
06 May 2021 |
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
|
|
04 May 2021 |
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
|
|
04 May 2021 |
Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine
|
|
30 Apr 2021 |
Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY® in the EU to Adolescents
|
|
24 Apr 2021 |
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
|
|
24 Apr 2021 |
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
|
|
22 Apr 2021 |
Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant
|
|
22 Apr 2021 |
Sirnaomics' Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development
|
|
18 Apr 2021 |
Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed
|
|
15 Apr 2021 |
INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
|
|
13 Apr 2021 |
Intravacc announces positive preclinical data for its OMV-based Lyme vaccine
|
|
13 Apr 2021 |
Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines
|
|
12 Apr 2021 |
Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine
|
|
12 Apr 2021 |
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
|
|
11 Apr 2021 |
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
|
